Hormonal
GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss through hormonal mechanisms but carry a high risk of psychological dependency and rebound weight gain upon discontinuation, necessitating their use as temporary adjuncts to lifestyle interventions rather than standalone long-term solutions.
If you are using GLP-1 drugs, treat them as a temporary bridge to build sustainable habits, not a permanent solution. Prioritize resistance training and protein intake to protect muscle mass, as rapid weight loss without exercise increases frailty risk. Plan for discontinuation early by integrating behavioral therapy and dietary changes to prevent rebound weight gain and dependency.
GLP-1 receptor agonists mimic the action of endogenous incretin hormones, stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite... emerging concerns highlight potential pharmaceutical dependency... patients often describe a fear of weight regain and a loss of control, reflecting a cycle of pharmacologic reliance... Pharmacotherapy should complement, not replace, evidence-based exercise and nutrition interventions.
Why this rating
The paper is a short communication/opinion piece citing other clinical trials and reports, rather than presenting primary empirical data itself.
Source
The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic
Peters Fredrick · Journal of Sports Medicine and Therapy · 2025
DOI 10.29328/journal.jsmt.1001096
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →